CISI FIN(06058.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at HKD 137.75 million, YoY increase of 33.82%
NewTimeSpace News:August 17, 2026, CISI FIN(06058.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at HKD 596.3 million, increased by 49.73% YoY; Net Profit stood at HKD 137.75 million, YoY increase of 33.82%; Profit Attributable to Shareholders stood at HKD 137.75 million, YoY increase of 33.82%; Basic Earnings Per Share (EPS) stood at HK cents 3.44.
In terms of profitability, CISI FIN net profit changed from HKD 102.93 million in the same period last year to HKD 137.75 million in the current period, increased by HKD 34.82 million; net profit margin changed from 25.85% in the same period last year to 23.1% in the current period, decreased by 2.75 percentage points.
In terms of earnings quality, CISI FIN Operating Profit changed from HKD 363.94 million in the same period last year to HKD 562.81 million in the current period, increased by HKD 198.87 million; Operating Profit Margin changed from 91.38% in the same period last year to 94.38% in the current period, increased by 3 percentage points.
In terms of financial soundness, CISI FIN Debt-to-Asset Ratio changed from 79.31% in the same period last year to 85.89% in the current period, increased by 6.58 percentage points; Total Equity changed from HKD 4.324 billion in the same period last year to HKD 4.559 billion in the current period, increased by HKD 235.48 million; Current Liabilities changed from HKD 15.11 billion in the same period last year to HKD 27.76 billion in the current period, increased by HKD 12.65 billion.
By the close of trading on August 17, 2026, CISI FIN(06058) saw a gain of 10.34% in its share price, closing at HKD 0.64. The full-day turnover stood at HKD 5.78 million, with the latest market capitalization at HKD 2.56 billion.
NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- MICOT PHARMA-B (02335.HK): Three XTL6001 Studies Accepted for Presentation at EASD 2026 and ASN Kidney Week 2026, Triple-Agonist Mechanism Gains International Recognition
- MICOT PHARMA-B (02335.HK): Preclinical and Phase I data of neuroprotective candidate MT200605 accepted for oral presentation at 2026 World Stroke Congress; Phase II meets primary endpoint
- Shaanxi Micot Pharmaceutical Technology (02335.HK): Phase II Trial of MT200605 for Acute Ischemic Stroke Meets Primary Endpoint
- Shaanxi Micot Pharmaceutical Technology Co., Ltd (02335.HK): Phase II Clinical Study of Dual-Function Antithrombotic Candidate MT1002 for Anticoagulation in Haemodialysis Completes First Patient Enrolment
- MICOT PHARMA-B(02335.HK) closed 102.75% higher, the Hang Seng Pharmaceuticals & Biotechnology Sector saw divergent trends